By Super User on Friday, 08 December 2023
Category: NLS Blog

Navitas Life Sciences Supports Efficient Clinical Trials for Advancing Treatment for HIV/AIDS

The World Health Organization states that nearly 39 million people live with HIV/AIDS globally (2022), with 630,000 people dying due to HIV related causes, necessitating the need for improved treatment and care. Navitas Life Sciences has been supporting the efficient management of clinical trials for small to large pharma and life sciences companies for over 30 years, helping support the market reach of life saving medicines, including for people with HIV/AIDS.

We have conducted 600+ clinical trials across 20+ different therapeutic areas, including infectious disease clinical trials. Our trial excellence is enhanced by our proprietary OneClinical® Analytics platform, providing oversight and key data insights.

Navitas Life Sciences’ Expertise and Experience in Managing HIV/AIDS Clinical Trials

Navitas Life Sciences has conducted numerous Phase I-IV HIV/AIDS clinical trials, across Germany, Thailand and India.

In our latest blog, Smitkumar Shah, Clinical Project Manager, Navitas Life Sciences explores the role of clinical trials and our comprehensive CRO services.

Smitkumar Shah

Clinical Project Manager,

Navitas Life Sciences

The Role of Clinical Trials and Our Comprehensive CRO Services

World AIDS Day, a recently celebrated awareness day aimed at raising understanding, prompts a reflection on the significant strides in HIV/AIDS medication. Many of these breakthroughs stem from dedicated clinical trials, underscoring the crucial role played by our comprehensive CRO services in advancing healthcare solutions.

A Landmark Discovery: The Efficacy of Tenofovir in HIV Prevention

One of the important moments in HIV/AIDS medication research stemmed from clinical trials investigating Tenofovir, a crucial component of HIV treatment and prevention. Notably, the iPrEx study, a pivotal Phase III clinical trial, demonstrated the efficacy of Tenofovir as Pre-Exposure Prophylaxis (PrEP). This trial involved high-risk populations and showcased that Tenofovir, when taken as a daily pill, significantly reduced the risk of HIV transmission.

Impact of Clinical Trials in HIV/AIDS Treatment

Clinical trials, like iPrEx, provided breakthroughs that transformed the landscape of HIV/AIDS treatment. However, behind such monumental discoveries stand organizations like ours, committed to delivering end-to-end services that drive these trials forward.

Navitas Life Sciences’ Role in Advancing HIV/AIDS Clinical Trials

At Navitas Life Sciences, we are at the forefront of supporting efficient clinical trials, including infectious diseases clinical trials, with our comprehensive suite of services:

As we celebrate achievements and acknowledge breakthroughs, let us also recognize the collaborative efforts that drive these advancements. At Navitas Life Sciences, we stand committed to spearheading and supporting HIV/AIDS clinical trials, paving the way for a brighter, healthier future for all.

END-TO-END CLINICAL RESEARCH CAPABILITIES

Learn more about how we can support your clinical trials by leveraging technology & analytics

To know more about our services and solutions, reach out to us at This email address is being protected from spambots. You need JavaScript enabled to view it..

« Return to blog

Leave Comments